148 results on '"Walts AE"'
Search Results
2. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer
- Author
-
Cohen, JG, Prendergast, E, Geddings, JE, Walts, AE, Agadjanian, H, Hisada, Y, Karlan, BY, Mackman, N, and Walsh, CS
- Subjects
Adult ,Oncology and Carcinogenesis ,and over ,Thromboplastin ,Paediatrics and Reproductive Medicine ,Ovarian cancer ,Neoplasms ,Enzyme Multiplied Immunoassay Technique ,Ovarian Epithelial ,80 and over ,Humans ,cardiovascular diseases ,Oncology & Carcinogenesis ,Neoplasm Staging ,Aged ,Clear cell carcinoma ,Ovarian Neoplasms ,Venous Thrombosis ,Carcinoma ,Glandular and Epithelial ,Middle Aged ,Immunohistochemistry ,Survival Analysis ,Tissue factor ,Case-Control Studies ,Female ,Microvesicles ,Venous thromboembolism - Abstract
ObjectiveOvarian clear cell carcinoma (OCCC) and high grade serous ovarian cancer (HGSOC) are associated with the highest risk of VTE among patients with epithelial ovarian cancer (EOC). Tissue factor (TF) is a transmembrane glycoprotein which can trigger thrombosis. We sought to evaluate if there is an association between VTE and tumor expression of tissue factor (TF), plasma TF, and microvesicle TF (MV TF) activity in this high-risk population.MethodsWe performed a case-control study of OCCC and HGSOC patients with and without VTE. 105 patients who underwent surgery at a tertiary care center between January 1995 and October 2013 were included. Plasma TF was measured with an enzyme-linked immunosorbent assay. A TF-dependent Factor Xa generation assay was used to measure MV TF activity. Immunohistochemical (IHC) analysis was performed to evaluate tumor expression of TF.Results35 women with OCCC or HGSOC diagnosed with VTE within 9months of surgery were included in the case group. Those with VTE had a worse OS, p
- Published
- 2017
3. FOXC2 augments tumor propagation and metastasis in osteosarcoma
- Author
-
Gozo, MC, Jia, D, Aspuria, P-J, Cheon, D-J, Miura, N, Walts, AE, Karlan, BY, and Orsulic, S
- Subjects
musculoskeletal diseases ,Lung Neoplasms ,Nude ,Oncology and Carcinogenesis ,Down-Regulation ,Bone Neoplasms ,Cell Line ,Mice ,Cell Movement ,anoikis ,osteosarcoma ,Receptors ,Cell Adhesion ,Animals ,Humans ,metastasis ,Neoplasm Invasiveness ,Gene Silencing ,Neoplasm Metastasis ,neoplasms ,CXCR4 ,Neoplastic ,Tumor ,forkhead box C2 ,Cell Differentiation ,Forkhead Transcription Factors ,invasion ,Gene Expression Regulation ,Neoplasm Transplantation ,Signal Transduction - Abstract
Osteosarcoma is a highly malignant tumor that contains a small subpopulation of tumor-propagating cells (also known as tumor-initiating cells) characterized by drug resistance and high metastatic potential. The molecular mechanism by which tumor-propagating cells promote tumor growth is poorly understood. Here, we report that the transcription factor forkhead box C2 (FOXC2) is frequently expressed in human osteosarcomas and is important in maintaining osteosarcoma cells in a stem-like state. In osteosarcoma cell lines, we show that anoikis conditions stimulate FOXC2 expression. Downregulation of FOXC2 decreases anchorage-independent growth and invasion in vitro and lung metastasis in vivo, while overexpression of FOXC2 increases tumor propagation in vivo. In osteosarcoma cell lines, we demonstrate that high levels of FOXC2 are associated with and required for the expression of osteosarcoma tumor-propagating cell markers. In FOXC2 knockdown cell lines, we show that CXCR4, a downstream target of FOXC2, can restore osteosarcoma cell invasiveness and metastasis to the lung.
- Published
- 2016
4. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
- Author
-
Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, and Karlan BY
- Published
- 2005
- Full Text
- View/download PDF
5. Amyloid, carpal tunnel syndrome, and chronic hemodialysis
- Author
-
Walts Ae, Matorin Pa, and Goodman
- Subjects
Male ,medicine.medical_specialty ,Resuscitation ,Amyloid ,business.industry ,Amyloidosis ,Maintenance hemodialysis ,Middle Aged ,Wrist ,medicine.disease ,Carpal Tunnel Syndrome ,Surgery ,Nephrology ,Renal Dialysis ,medicine ,Humans ,Chronic hemodialysis ,Female ,Complication ,Intensive care medicine ,business ,Carpal tunnel syndrome - Published
- 1985
6. Robotic-Assisted Bronchoscopy for the Diagnosis of Lung Lesions: Experience With the Use of Frozen Sections as an Aid to Confirm the Localization of Lesions During the Procedure.
- Author
-
Kanathanavanich M, Li X, Boac B, Bose S, Walts AE, Imai T, Chaux G, Brownlee A, and Marchevsky AM
- Abstract
Context.—: Robotic-assisted navigation bronchoscopy (R-ANB) is used to target peripheral pulmonary nodules that are difficult to biopsy using conventional approaches. Frozen sections are requested to confirm these lesions have been localized and/or to diagnose neoplasms that can be immediately resected., Objective.—: To estimate diagnostic concordance between frozen section diagnosis (FSD) and formalin-fixed tissue diagnosis (FFTD) in biopsies obtained with R-ANB, calculate the sensitivity and specificity of FSD and FFTD for a diagnosis of malignancy, and evaluate whether the residual tissue that can be fixed in formalin after frozen section still has sufficient material for molecular studies., Data Sources.—: The results of consecutive FSD rendered on biopsies performed with R-ANB during a 30-month period were used to calculate the metrics listed above. FFTD and/or the diagnoses rendered on computed tomography-guided core biopsy subsequently performed in patients with negative R-ANB and/or lung resections in patients with malignancies were used as true-positive results. The overall concordance between FSD and FFTD in 226 lesions from 203 patients was 72%. Frozen section diagnosed 76 of 123 malignancies with 100% specificity and 68% sensitivity. Adequate material was available in 92% of biopsies where next-generation sequencing and other molecular studies were requested., Conclusions.—: Intraoperative consultations are helpful to diagnose a variety of lung lesions and help surgeons confirm that targets have been accurately reached by R-ANB. Malignancies can be diagnosed with 100% specificity but only 68% sensitivity. The performance of frozen section did not interfere with the subsequent analysis of tissue with molecular studies in most cases., Competing Interests: The authors have no relevant financial interest in the products or companies described in this article., (© 2024 College of American Pathologists.)
- Published
- 2024
- Full Text
- View/download PDF
7. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
- Author
-
Xu AM, Haro M, Walts AE, Hu Y, John J, Karlan BY, Merchant A, and Orsulic S
- Subjects
- Female, Humans, Neoplasm Recurrence, Local, Recurrence, Tumor Microenvironment, Cancer-Associated Fibroblasts pathology, Antineoplastic Agents therapeutic use, Ovarian Neoplasms drug therapy
- Abstract
High-grade serous ovarian carcinoma (HGSOC), the deadliest form of ovarian cancer, is typically diagnosed after it has metastasized and often relapses after standard-of-care platinum-based chemotherapy, likely due to advanced tumor stage, heterogeneity, and immune evasion and tumor-promoting signaling from the tumor microenvironment. To understand how spatial heterogeneity contributes to HGSOC progression and early relapse, we profiled an HGSOC tissue microarray of patient-matched longitudinal samples from 42 patients. We found spatial patterns associated with early relapse, including changes in T cell localization, malformed tertiary lymphoid structure (TLS)-like aggregates, and increased podoplanin-positive cancer-associated fibroblasts (CAFs). Using spatial features to compartmentalize the tissue, we found that plasma cells distribute in two different compartments associated with TLS-like aggregates and CAFs, and these distinct microenvironments may account for the conflicting reports about the role of plasma cells in HGSOC prognosis.
- Published
- 2024
- Full Text
- View/download PDF
8. Guidelines for Pathologic Diagnosis of Mesothelioma.
- Author
-
Husain AN, Chapel DB, Attanoos R, Beasley MB, Brcic L, Butnor K, Chirieac LR, Churg A, Dacic S, Galateau-Salle F, Hiroshima K, Hung YP, Klebe S, Krausz T, Khoor A, Litzky L, Marchevsky A, Nabeshima K, Nicholson AG, Pavlisko EN, Roden AC, Roggli V, Sauter JL, Schulte JJ, Sheaff M, Travis WD, Tsao MS, Walts AE, and Colby TV
- Abstract
Context.—: Mesothelioma is an uncommon tumor that can be difficult to diagnose., Objective.—: To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma., Data Sources.—: Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks., Conclusions.—: There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions., Competing Interests: The authors have no relevant financial interest in the products or companies described in this article., (© 2024 College of American Pathologists.)
- Published
- 2024
- Full Text
- View/download PDF
9. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer.
- Author
-
Hu Y, Recouvreux MS, Haro M, Taylan E, Taylor-Harding B, Walts AE, Karlan BY, and Orsulic S
- Abstract
Effective targeting of cancer-associated fibroblasts (CAFs) is hindered by the lack of specific biomarkers and a poor understanding of the mechanisms by which different populations of CAFs contribute to cancer progression. While the role of TGFβ in CAFs is well-studied, less attention has been focused on a structurally and functionally similar protein, Activin A (encoded by INHBA). Here, we identified INHBA(+) CAFs as key players in tumor promotion and immunosuppression. Spatiotemporal analyses of patient-matched primary, metastatic, and recurrent ovarian carcinomas revealed that aggressive metastatic tumors enriched in INHBA(+) CAFs were also enriched in regulatory T cells (Tregs). In ovarian cancer mouse models, intraperitoneal injection of the Activin A neutralizing antibody attenuated tumor progression and infiltration with pro-tumorigenic subsets of myofibroblasts and macrophages. Downregulation of INHBA in human ovarian CAFs inhibited pro-tumorigenic CAF functions. Co-culture of human ovarian CAFs and T cells revealed the dependence of Treg differentiation on direct contact with INHBA(+) CAFs. Mechanistically, INHBA/recombinant Activin A in CAFs induced the autocrine expression of PD-L1 through SMAD2-dependent signaling, which promoted Treg differentiation. Collectively, our study identified an INHBA(+) subset of immunomodulatory pro-tumoral CAFs as a potential therapeutic target in advanced ovarian cancers which typically show a poor response to immunotherapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Multilayer outperforms single-layer slide scanning in AI-based classification of whole slide images with low-burden acid-fast mycobacteria (AFB).
- Author
-
Nurzynska K, Li D, Walts AE, and Gertych A
- Subjects
- Microscopy, Artificial Intelligence
- Abstract
Manual screening of Ziehl-Neelsen (ZN)-stained slides that are negative or contain rare acid-fast mycobacteria (AFB) is labor-intensive and requires repetitive refocusing to visualize AFB candidates under the microscope. Whole slide image (WSI) scanners have enabled implementation of AI to classify digital ZN-stained slides as AFB+ or AFB-. By default, these scanners acquire a single-layer WSI. However, some scanners can acquire a multilayer WSI with a z-stack and an extended focus image layer embedded. We developed a parameterized WSI classification pipeline to assess whether multilayer imaging improves ZN-stained slide classification accuracy. A CNN built into the pipeline classified tiles in each image layer to form an AFB probability score heatmap. Features extracted from the heatmap were then entered into a WSI classifier. 46 AFB+ and 88 AFB- single-layer WSIs were used for the classifier training. 15 AFB+ (with rare microorganisms) and 5 AFB- multilayer WSIs comprised the test set. Parameters in the pipeline included: (a) a WSI representation: z-stack of image layers, middle image layer (a single image layer equivalent) or an extended focus image layer, (b) 4 methods of aggregating AFB probability scores across the z-stack, (c) 3 classifiers, (d) 3 AFB probability thresholds, and (e) 9 feature vector types extracted from the aggregated AFB probability heatmaps. Balanced accuracy (BACC) was used to measure the pipeline performance for all parameter combinations. Analysis of Covariance (ANCOVA) was used to statistically evaluate the effect of each parameter on the BACC. After adjusting for other factors, a significant effect of the WSI representation (p-value < 1.99E-76), classifier type (p-value < 1.73E-21), and AFB threshold (p-value = 0.003) was observed on the BACC. The feature type had no significant effect (p-value = 0.459) on the BACC. WSIs represented by the middle layer, extended focus layer and the z-stack followed by the weighted averaging of AFB probability scores were classified with the average BACC of 58.80%, 68.64%, and 77.28%, respectively. The multilayer WSIs represented by the z-stack with the weighted averaging of AFB probability scores were classified by a Random Forest classifier with the average BACC of 83.32%. Low classification accuracy of WSIs represented by the middle layer suggests that they contain fewer features permitting identification of AFB than the multilayer WSIs. Our results indicate that single-layer acquisition can introduce a bias (sampling error) into the WSI. This bias can be mitigated by the multilayer or the extended focus acquisitions., Competing Interests: Declaration of Competing Interest The authors report no declarations of interest., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.
- Author
-
Richardson MT, Recouvreux MS, Karlan BY, Walts AE, and Orsulic S
- Subjects
- Humans, Female, Carcinoma, Ovarian Epithelial pathology, Epithelial Cells metabolism, Fallopian Tubes metabolism, Disease Progression, Ovarian Neoplasms pathology
- Abstract
Ciliated cell markers expressed in epithelial ovarian cancers (EOC) are associated with improved survival. We examined the distribution of cells expressing ciliated cell markers in various EOC histologies and stages. Immunohistochemistry and/or multiplex immunofluorescence were used to determine the expression of FOXJ1 and/or CAPS (ciliated cell markers) in tissue microarrays including 4 normal fallopian tubes, 6 normal endometria, 16 cystadenomas, 25 borderline tumors, 21 low-grade carcinomas, and 118 high-grade carcinomas (HGSOC) (46 serous, 29 endometrioid, 30 clear cell, 13 mucinous). CAPS+ cells were observed in normal fallopian tubes and endometria and in ~85% of serous benign and borderline tumors and low-grade carcinomas but only in <40% of HGSOC. mRNA data from an independent cohort showed higher FOXJ1 and CAPS expression in serous borderline tumors and low-grade carcinomas compared to HGSOC. In HGSOC, ciliated cell-positive markers were observed in 52% primary tumors compared to 26% of patient-matched synchronous metastases, and 24% metachronous metastases ( p = 0.009). mRNA data from an independent HGSOC cohort showed lower levels of CAPS in metastases than in primary tumors ( p = 0.03). Overall, the study revealed that ciliated cells were less common in mucinous EOC, the percentage of ciliated cell marker-positive cases decreased with increasing grade, and the percentage of ciliated cells decreased in HGSOC metastases compared to patient-matched primary tumors.
- Published
- 2022
- Full Text
- View/download PDF
12. Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers.
- Author
-
Gertych A, Walts AE, Cheng K, Liu M, John J, Lester J, Karlan BY, and Orsulic S
- Subjects
- Humans, Female, Neoplasm Recurrence, Local, Carcinoma, Ovarian Epithelial, Extracellular Matrix pathology, Tumor Microenvironment, CD8-Positive T-Lymphocytes pathology, Ovarian Neoplasms genetics
- Abstract
Cancer-associated fibroblasts (CAFs) and their extracellular matrix are active participants in cancer progression. While it is known that functionally different subpopulations of CAFs co-exist in ovarian cancer, it is unclear whether certain CAF subsets are enriched during metastatic progression and/or chemotherapy. Using computational image analyses of patient-matched primary high-grade serous ovarian carcinomas, synchronous pre-chemotherapy metastases, and metachronous post-chemotherapy metastases from 42 patients, we documented the dynamic spatiotemporal changes in the extracellular matrix, fibroblasts, epithelial cells, immune cells, and CAF subsets expressing different extracellular matrix components. Among the different CAF subsets, COL11A1
+ CAFs were associated with linearized collagen fibers and exhibited the greatest enrichment in pre- and post-chemotherapy metastases compared to matched primary tumors. Although pre- and post-chemotherapy metastases were associated with increased CD8+ T cell infiltration, the infiltrate was not always evenly distributed between the stroma and cancer cells, leading to an increased frequency of the immune-excluded phenotype where the majority of CD8+ T cells are present in the tumor stroma but absent from the tumor parenchyma. Overall, most of the differences in the tumor microenvironment were observed between primary tumors and metastases, while fewer differences were observed between pre- and post-treatment metastases. These data suggest that the tumor microenvironment is largely determined by the primary vs. metastatic location of the tumor while chemotherapy does not have a significant impact on the host microenvironment.- Published
- 2022
- Full Text
- View/download PDF
13. FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer.
- Author
-
Recouvreux MS, Miao J, Gozo MC, Wu J, Walts AE, Karlan BY, and Orsulic S
- Abstract
FOXC2 is a forkhead family transcription factor that plays a critical role in specifying mesenchymal cell fate during embryogenesis. FOXC2 expression is associated with increased metastasis and poor survival in various solid malignancies. Using in vitro and in vivo assays in mouse ovarian cancer cell lines, we confirmed the previously reported mechanisms by which FOXC2 could promote cancer growth, metastasis, and drug resistance, including epithelial-mesenchymal transition, stem cell-like differentiation, and resistance to anoikis. In addition, we showed that FOXC2 expression is associated with vasculogenic mimicry in mouse and human ovarian cancers. FOXC2 overexpression increased the ability of human ovarian cancer cells to form vascular-like structures in vitro, while inhibition of FOXC2 had the opposite effect. Thus, we present a novel mechanism by which FOXC2 might contribute to cancer aggressiveness and poor patient survival.
- Published
- 2022
- Full Text
- View/download PDF
14. Computational pathology in ovarian cancer.
- Author
-
Orsulic S, John J, Walts AE, and Gertych A
- Abstract
Histopathologic evaluations of tissue sections are key to diagnosing and managing ovarian cancer. Pathologists empirically assess and integrate visual information, such as cellular density, nuclear atypia, mitotic figures, architectural growth patterns, and higher-order patterns, to determine the tumor type and grade, which guides oncologists in selecting appropriate treatment options. Latent data embedded in pathology slides can be extracted using computational imaging. Computers can analyze digital slide images to simultaneously quantify thousands of features, some of which are visible with a manual microscope, such as nuclear size and shape, while others, such as entropy, eccentricity, and fractal dimensions, are quantitatively beyond the grasp of the human mind. Applications of artificial intelligence and machine learning tools to interpret digital image data provide new opportunities to explore and quantify the spatial organization of tissues, cells, and subcellular structures. In comparison to genomic, epigenomic, transcriptomic, and proteomic patterns, morphologic and spatial patterns are expected to be more informative as quantitative biomarkers of complex and dynamic tumor biology. As computational pathology is not limited to visual data, nuanced subvisual alterations that occur in the seemingly "normal" pre-cancer microenvironment could facilitate research in early cancer detection and prevention. Currently, efforts to maximize the utility of computational pathology are focused on integrating image data with other -omics platforms that lack spatial information, thereby providing a new way to relate the molecular, spatial, and microenvironmental characteristics of cancer. Despite a dire need for improvements in ovarian cancer prevention, early detection, and treatment, the ovarian cancer field has lagged behind other cancers in the application of computational pathology. The intent of this review is to encourage ovarian cancer research teams to apply existing and/or develop additional tools in computational pathology for ovarian cancer and actively contribute to advancing this important field., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Orsulic, John, Walts and Gertych.)
- Published
- 2022
- Full Text
- View/download PDF
15. Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.
- Author
-
Wu J, Raz Y, Recouvreux MS, Diniz MA, Lester J, Karlan BY, Walts AE, Gertych A, and Orsulic S
- Abstract
Objective: Serous tubal intra-epithelial carcinoma (STIC) lesions are thought to be precursors to high-grade serous ovarian cancer (HGSOC), but HGSOC is not always accompanied by STIC. Our study was designed to determine if there are global visual and subvisual microenvironmental differences between fallopian tubes with and without STIC lesions., Methods: Computational image analyses were used to identify potential morphometric and topologic differences in stromal and epithelial cells in samples from three age-matched groups of fallopian tubes. The Benign group comprised normal fallopian tubes from women with benign conditions while the STIC and NoSTIC groups consisted of fallopian tubes from women with HGSOC, with and without STIC lesions, respectively. For the morphometric feature extraction and analysis of the stromal architecture, the image tiles in the STIC group were further divided into the stroma away from the STIC (AwaySTIC) and the stroma near the STIC (NearSTIC). QuPath software was used to identify and quantitate secretory and ciliated epithelial cells. A secretory cell expansion (SCE) or a ciliated cell expansion (CCE) was defined as a monolayered contiguous run of >10 secretory or ciliated cells uninterrupted by the other cell type., Results: Image analyses of the tubal stroma revealed gradual architectural differences from the Benign to NoSTIC to AwaySTIC to NearSTIC groups. In the epithelial topology analysis, the relative number of SCE and the average number of cells within SCE were higher in the STIC group than in the Benign and NoSTIC groups. In addition, aging was associated with an increased relative number of SCE and a decreased relative number of CCE. ROC analysis determined that an average of 15 cells within SCE was the optimal cutoff value indicating the presence of a STIC lesion in the tubal epithelium., Conclusions: Our findings suggest that global stromal alterations and age-associated reorganization of tubal secretory and ciliated cells are associated with STIC lesions. Further studies will need to determine if these alterations precede STIC lesions and provide permissible conditions for the formation of STIC., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Wu, Raz, Recouvreux, Diniz, Lester, Karlan, Walts, Gertych and Orsulic.)
- Published
- 2022
- Full Text
- View/download PDF
16. Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis.
- Author
-
Schulte JJ, Chapel DB, Attanoos R, Brcic L, Burn J, Butnor KJ, Chang N, Chen H, Dacic S, De Perrot M, Fukuoka J, Galateau-Salle F, Godschachner T, Hiroshima K, Klebe S, Krausz T, Litzky L, Marchevsky AM, Mueller J, Nabeshima K, Nicholson AG, Pal P, Roden AC, Rorvig S, Santoni-Rugiu E, Tazelaar H, Tsao MS, Walts AE, Weynand B, Zaizen Y, Zhang YZ, and Husain AN
- Subjects
- Biopsy, Humans, Necrosis, Prognosis, Mesothelioma, Malignant pathology, Mesothelioma, Malignant surgery, Pleural Neoplasms pathology, Pleural Neoplasms surgery
- Abstract
Objectives: Numerous studies on malignant mesothelioma (MM) highlight the prognostic importance of histologic subtype, nuclear grade, and necrosis. This study compares these parameters in paired biopsy and resection specimens of pleural MM., Methods: Histologic subtype, percentage of epithelioid morphology, nuclear grade, and the presence or absence of necrosis were compared in 429 paired biopsies and resection specimens of pleural MM from 19 institutions., Results: Histologic subtype was concordant in 81% of cases (κ = 0.58). When compared with resection specimens, epithelioid morphology at biopsy had a positive predictive value (PPV) of 78.9% and a negative predictive value (NPV) of 93.5%; sarcomatoid morphology showed high PPV (92.9%) and NPV (99.3%), and biphasic morphology PPV was 89.7% and NPV was 79.7%. Agreement of the percentage of epithelioid morphology was fair (κ = 0.27). Nuclear grade and necrosis were concordant in 75% (κ = 0.59) and 81% (κ = 0.53) of cases, respectively. Nuclear grade showed moderate (κ = 0.53) and substantial (κ = 0.67) agreement from patients with and without neoadjuvant therapy, respectively, and necrosis showed moderate (κ = 0.47 and κ = 0.60) agreement, respectively, in the same subsets of paired specimens., Conclusions: Paired biopsy-resection specimens from pleural MM show overall moderate agreement in pathologic parameters. These findings may help guide postbiopsy management and triage of patients with MM., (© American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
17. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.
- Author
-
Hiroshima K, Wu D, Koh E, Sekine Y, Ozaki D, Yusa T, Nakazawa T, Tsuji S, Miyagi Y, Walts AE, Marchevsky AM, Husain AN, and Imai K
- Subjects
- Carcinoma, Squamous Cell pathology, Diagnosis, Differential, Epithelium pathology, Humans, Immunohistochemistry, Lung Neoplasms pathology, Membrane Proteins genetics, Mesothelioma, Malignant pathology, Tissue Array Analysis, Carcinoma, Squamous Cell diagnosis, Lung Neoplasms diagnosis, Membrane Proteins metabolism, Mesothelioma, Malignant diagnosis
- Abstract
Sialylated HEG1 has been reported as a highly specific and sensitive mesothelioma marker but a comprehensive evaluation of its expression in carcinomas in different organs, various sarcomas and reactive mesothelial proliferations has not been reported. The aim of this study was to evaluate the clinical applicability of HEG1 as a marker in the diagnosis of mesothelioma. HEG1 immunoreactivity was evaluated in whole sections of 122 mesotheliomas, 75 pulmonary carcinomas, 55 other carcinomas, 16 mesenchymal tumors, and 24 reactive mesothelial proliferations and in tissue microarrays containing 70 epithelioid (EM), 36 biphasic (BM), and 2 sarcomatoid mesotheliomas (SM). In whole sections and tissue microarrays, respectively, membranous HEG1 was expressed in 93.0% and 85.5% of EM, 81.3% and 69.4% of BM, 0% and 0% of SM. HEG1 was not expressed in pulmonary adenocarcinomas. HEG1 was expressed as cytoplasmic immunoreactivity in pulmonary squamous cell carcinomas (21.7%). Membranous HEG1 staining was seen in ovarian carcinomas (66.7%), thyroid carcinomas (100%), reactive conditions (16.7%), and mesenchymal tumors (18.8%). The sensitivity of membranous HEG1 expression to distinguish EM/BM from all carcinomas was 88.8%. The specificity for the differential diagnosis between EM/BM and all carcinomas and pulmonary carcinomas was 92.3% and 98.7%, respectively., (© 2021 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
18. Clinico-pathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome).
- Author
-
Chaum M, Shouhed D, Kim S, Walts AE, and Marchevsky AM
- Subjects
- Abdominal Pain etiology, Adult, Body Mass Index, Celiac Artery surgery, Celiac Plexus surgery, Constriction, Pathologic etiology, Female, Fibrosis surgery, Ganglia, Sympathetic surgery, Humans, Laparoscopy methods, Median Arcuate Ligament Syndrome diagnosis, Median Arcuate Ligament Syndrome surgery, Middle Aged, Nausea etiology, Nerve Block methods, Outcome Assessment, Health Care, Postprandial Period, Robotic Surgical Procedures methods, Vomiting etiology, Weight Loss, Celiac Artery pathology, Celiac Plexus pathology, Fibrosis pathology, Ganglia, Sympathetic pathology, Median Arcuate Ligament Syndrome pathology
- Abstract
Median Arcuate Ligament Syndrome (MALS) is a rare entity characterized by severe post-prandial epigastric pain, nausea, vomiting, and/or weight loss. Symptoms have been attributed to vascular compression (celiac artery compression syndrome, CACS), but it remains controversial whether they could be secondary to neural compression. Literature review identified rare description of pathologic findings in surgery journals. The clinico-pathologic findings of four MALS patients who underwent robotic or laparoscopic surgery in our hospital are described. All our patients were female with a median age of 32.5 (range 25-55 years), and a median BMI of 23.5 kg/m
2 . They presented with chronic often post-prandial abdominal pain (4/4), nausea (3/4), emesis (2/4), anorexia (1/4), and weight loss (1/4). Two patients had a history of Crohn's disease. At intraoperative exploration, the celiac artery and adjacent nerves and ganglia were encased and partially compressed by fibrotic tissue in each patient. In each case laparoscopic excision of fibrotic tissue, celiac plexus and ligament division and was performed; celiac plexus nerve block was also performed in one patient. After surgical intervention, symptoms improved in three of the patients whose specimens show periganglionic and perineural fibrosis with proliferation of small nerve fibers. Our findings support neurogenic compression as a contributing factor in the development of pain and other MALS symptoms, and favor the use of MALS rather than CACS as diagnostic terminology. To further study the pathogenesis of this unusual syndrome, surgeons should submit all tissues excised during MALS procedures for histopathologic examination., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
19. The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis.
- Author
-
Klebe S, Nakatani Y, Dobra K, Butnor KJ, Roden AC, Nicholson AG, Marchevsky AM, Husain AN, Segal A, Walts AE, Weynand B, Michael CW, Dacic S, Godbolt D, Attanoos R, Santoni-Rugiu E, Galateau-Salle F, Hiroshima K, Moreira AL, Burn J, Nabeshima K, Gibbs AR, Churg A, Litzky LA, Brcic L, Tsao MS, Mino-Kenudson M, Rørvig SB, Tazelaar HD, Krausz T, Zhang YZ, Chirieac LR, Beasley MB, and Hjerpe A
- Subjects
- Cytodiagnosis, Early Diagnosis, Humans, Mesothelioma, Malignant classification, Mesothelioma, Malignant pathology, Mesothelioma, Malignant therapy, Pathologists, Serous Membrane pathology, Surveys and Questionnaires, World Health Organization, Mesothelioma, Malignant diagnosis
- Abstract
Diffuse malignant mesothelioma (MM) is an incurable tumour of the serosal membranes, which is often caused by exposure to asbestos and commonly diagnosed at advanced stage. Malignant mesothelioma in situ (MMIS) is now included as diagnostic category by the World Health Organization (WHO). However, our international survey of 34 pulmonary pathologists with an interest in MM diagnosis highlights inconsistency regarding how the diagnosis is being made by experts, despite published guidelines. Whilst the WHO restricts the diagnosis to surgical samples, the very concept has implication for cytological diagnosis, which is already regarded as controversial in itself by some. MMIS is currently only applicable as precursor to MM with an epithelioid component, and raises the possibility for different molecular pathways for different histological MM subtypes. The clinical implications of MMIS at this stage are uncertain, but aggressive therapies are being initiated in some instances. Based on the results of the survey we here present a critical appraisal of the concept, its clinical and conceptual implications and provide practice suggestions for diagnosis. A low threshold for ancillary testing is suggested. The designations of 'malignant mesothelioma, cannot exclude MMIS' or 'atypical mesothelial proliferation with molecular indicators of malignancy, so-called MMIS' could be used on cytology samples, adding 'no evidence of invasion in sample provided' for surgical samples. Clinical and radiological correlation are integral to diagnosis and best done at multidisciplinary meetings. Finally, collaborative studies are required to improve our understanding of MMIS., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
20. Challenges in Ki-67 assessments in pulmonary large-cell neuroendocrine carcinomas.
- Author
-
Walts AE, Mirocha JM, and Marchevsky AM
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Male, Middle Aged, Carcinoma, Large Cell diagnosis, Carcinoma, Large Cell pathology, Carcinoma, Neuroendocrine diagnosis, Carcinoma, Neuroendocrine pathology, Ki-67 Antigen analysis, Prognosis
- Abstract
Aims: To gather the best available evidence regarding Ki-67% values in large-cell neuroendocrine carcinoma (LCNEC) and determine whether certain cut-off values could serve as a prognostic feature in LCNEC., Methods and Results: Aperio ScanScope AT Turbo, eSlide Manager and ImageScope software (Leica Biosystems) were used to measure Ki-67% in 77 resected LCNEC diagnosed by World Health Organisation (WHO) criteria. Cases were stratified into six classes by 10% Ki-67 increments. Using the Kaplan-Meier method, overall (OS) and disease-free survivals (DFS) were compared by AJCC stage, by six Ki-67% classes and with Ki-67% cut-points ≥20% and ≥40%. Tumours were from 0.9 to 11.5 cm and pathological stages 1-3. The system measured Ki-67% positivity using 4072-44 533 tumour nuclei per case (mean 16610 ± 8039). Ki-67% ranged from 1 to 64% (mean = 26%; median = 26%). Only 16 (21%) tumours had Ki-67% ≥40%. OS ranged from 1 to 298 months (median follow-up = 25 months). DFS ranged from 1 to 276 months (median follow-up = 9 months). OS and DFS differed across AJCC stage (overall log-rank P = 0.038 and P = 0.037). However, neither OS nor DFS significantly correlated with Ki-67% when six or two classes were used with either ≥20% Ki-67 or ≥40% Ki-67 as cut-point. A literature review identified 14 reports meeting our inclusion criteria with ≥10 LCNEC. Reported Ki-67% ranged from 2% to 100%. Problems contributing to variability in Ki-67% measurements are discussed., Conclusion: Our findings caution against a blanket use of 20%, 40% or other Ki-67% cut-points for LCNEC diagnosis or prognostication., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
21. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
- Author
-
Chapel DB, Schulte JJ, Absenger G, Attanoos R, Brcic L, Butnor KJ, Chirieac L, Churg A, Galateau-Sallé F, Hiroshima K, Hung YP, Kindler H, Krausz T, Marchevsky A, Mino-Kenudson M, Mueller J, Nabeshima K, Turaga K, Walts AE, and Husain AN
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Cell Nucleus pathology, Disease-Free Survival, Female, Humans, Male, Middle Aged, Mitotic Index, Prognosis, Young Adult, Mesothelioma, Malignant pathology, Neoplasm Grading methods, Peritoneal Neoplasms pathology
- Abstract
Malignant peritoneal mesothelioma historically carried a grim prognosis, but outcomes have improved substantially in recent decades. The prognostic significance of clinical, morphologic, and immunophenotypic features remains ill-defined. This multi-institutional cohort comprises 225 malignant peritoneal mesotheliomas, which were assessed for 21 clinical, morphologic, and immunohistochemical parameters. For epithelioid mesotheliomas, combining nuclear pleomorphism and mitotic index yielded a composite nuclear grade, using a previously standardized grading system. Correlation of clinical, morphologic, and immunohistochemical parameters with overall and disease-free survival was examined by univariate and multivariate analyses. On univariate analysis, longer overall survival was significantly associated with diagnosis after 2000 (P = 0.0001), age <60 years (P = 0.0001), ECOG performance status 0 or 1 (P = 0.01), absence of radiographic lymph-node metastasis (P = 0.04), cytoreduction surgery (P < 0.0001), hyperthermic intraperitoneal chemotherapy (P = 0.0001), peritoneal carcinomatosis index <27 (P = 0.01), absence of necrosis (P = 0.007), and epithelioid histotype (P < 0.0001). Among epithelioid malignant mesotheliomas only, longer overall survival was further associated with female sex (P = 0.03), tubulopapillary architecture (P = 0.005), low nuclear pleomorphism (P < 0.0001), low mitotic index (P = 0.0007), and low composite nuclear grade (P < 0.0001). On multivariate analyses, the low composite nuclear grade was independently associated with longer overall and disease-free survival (P < 0.0001). Our data further clarify the interactions of clinical and pathologic features in peritoneal mesothelioma prognosis and validate the prognostic significance of a standardized nuclear-grading system in epithelioid malignant mesothelioma of the peritoneum.
- Published
- 2021
- Full Text
- View/download PDF
22. Reply to Letter to the Editor by William Gooding and Simion Chiosea: Alternate diagnostic test interpretation in a retrospective convenience cohort and clinical application of MPTX.
- Author
-
Lupo MA, Walts AE, Sistrunk JW, Massoll N, Campbell R, Jackson SA, Toney N, Narick CM, Kumar G, Mireskandari A, Finkelstein SD, and Bose S
- Subjects
- Humans, Retrospective Studies, Diagnostic Tests, Routine
- Published
- 2021
- Full Text
- View/download PDF
23. Multiplatform molecular test performance in indeterminate thyroid nodules.
- Author
-
Lupo MA, Walts AE, Sistrunk JW, Giordano TJ, Sadow PM, Massoll N, Campbell R, Jackson SA, Toney N, Narick CM, Kumar G, Mireskandari A, Finkelstein SD, and Bose S
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Biopsy, Fine-Needle methods, Female, Humans, Male, MicroRNAs genetics, Middle Aged, Mutation genetics, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Thyroid Gland pathology, Thyroid Neoplasms diagnosis, Thyroid Neoplasms genetics, Thyroid Neoplasms pathology, Thyroid Nodule genetics, Young Adult, Thyroid Nodule diagnosis, Thyroid Nodule pathology
- Abstract
Background: Approximately 25% of thyroid nodule fine-needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery., Methods: We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance., Results: Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%-99%) and 90% specificity (95% CI,84%-95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%-99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%-86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%-54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded., Conclusions: Our results emphasize that decisions for surgery should not solely be based on RAS or RAS-like mutations. MPTX informs management decisions while accounting for these challenges., (© 2020 The Authors. Diagnostic Cytopathology published by Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
24. A CNN-based active learning framework to identify mycobacteria in digitized Ziehl-Neelsen stained human tissues.
- Author
-
Yang M, Nurzynska K, Walts AE, and Gertych A
- Subjects
- Humans, Machine Learning, Neural Networks, Computer, Mycobacterium
- Abstract
Tuberculosis is the most common mycobacterial disease that affects humans worldwide. Rapid and reliable diagnosis of mycobacteria is crucial to identify infected individuals, to initiate and monitor treatment and to minimize or prevent transmission. Microscopic identification of acid-fast mycobacteria (AFB) in tissue sections is usually accomplished by examining Ziehl-Neelsen (ZN) stained slides in which AFB appear bright red against the blue background. Because the ZN-stained slides require time consuming and meticulous screening by an experienced pathologist, our team developed a machine learning pipeline to classify digitized ZN-stained slides as AFB-positive or AFB-negative. The pipeline includes two convolutional neural network (CNN) models to recognize tiles containing AFB, and a logistic regression (LR) model to classify slides based on features from AFB-probability maps assembled from the CNN tile-based classification results. The first CNN was trained using tiles from 6 AFB-positive and 8 AFB-negative slides, and the second CNN was trained using the initial tile set expanded by additional tiles from 19 AFB-negative slides selected within an active learning framework. When evaluated on a separate set of tiles, the two CNNs yielded F1 scores of 99.03% and 98.75%, respectively, and were used to classify tiles in a separate set of 134 slides (46 AFB-positive and 88 AFB-negative). The classification yielded two AFB-probability maps, one for each CNN. The LR model was then 10-fold cross-validated using the average of feature vectors extracted from the AFB-probability maps generated by each CNN. The feature vector consisted of seven features of the AFB-probability map histogram and the positive tile rate (PTR). The sensitivity (87.13%), specificity (87.62%) and F1 (80.18%) achieved by this model were superior to the baseline performance of PTR-based separation of slides that yielded F1 scores of 73.13% and 66.67% in the AFB-probability maps outputted by the CNN trained within the active learning framework and the CNN trained only on the initial set of slides, respectively. Our CNNs outperformed several recently published models for AFB detection. Active learning induced robust learning of features by the CNN and led to improved LR classification performance of slides. In the 52 AFB-positive slides used in the pipeline development, the AFB were infrequent, predominantly single and only rarely found in small clusters. Our pipeline can classify slides and visualize suspected AFB-positive areas in each slide, and thus potentially facilitate evaluation of ZN-stained tissue sections for AFB., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
25. HOXB13 controls cell state through super-enhancers.
- Author
-
Aspuria PJ, Cheon DJ, Gozo MC, Beach JA, Recouvreux MS, Walts AE, Karlan BY, and Orsulic S
- Subjects
- Bone and Bones metabolism, Cell Differentiation genetics, Gene Expression Regulation genetics, Genes, Homeobox genetics, Humans, Transcription Factors metabolism, Cell Differentiation physiology, Homeodomain Proteins metabolism, Mesenchymal Stem Cells cytology, Osteogenesis physiology
- Abstract
Expression of the homeodomain transcription factor HOXB13 has been demonstrated in several malignancies but its role in tumorigenesis remains elusive. We observed high levels of HOXB13 in poorly differentiated pediatric tumors including a highly aggressive childhood neoplasm - malignant rhabdoid tumor. In a xenograft model of rhabdoid tumor, knockout of HOXB13 diminished tumor growth while partial knockdown of HOXB13 promoted differentiation of tumor cells into bone. These results suggest that HOXB13 enhances rhabdoid malignancy by interfering with mesenchymal stem cell differentiation. Consistent with this hypothesis, overexpression of HOXB13 in mesenchymal progenitor cells inhibited adipogenic, myogenic, and osteogenic differentiation. Mechanistically, we demonstrated that HOXB13 binds to super-enhancer regions regulating genes involved in differentiation and tumorigenesis., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
26. Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability.
- Author
-
Marchevsky AM, Walts AE, Lissenberg-Witte BI, and Thunnissen E
- Subjects
- Benchmarking methods, Consensus, Diagnostic Techniques and Procedures trends, Evidence-Based Medicine methods, Humans, Observer Variation, Pathology standards, Predictive Value of Tests, Research Design trends, Sensitivity and Specificity, Statistics as Topic, Benchmarking statistics & numerical data, Diagnostic Techniques and Procedures statistics & numerical data, Lung pathology, Neuroendocrine Tumors diagnosis, Pathologists standards
- Abstract
Kappa statistics have been widely used in the pathology literature to compare interobserver diagnostic variability (IOV) among different pathologists but there has been limited discussion about the clinical significance of kappa scores. Five representative and recent pathology papers were queried using clinically relevant specific questions to learn how IOV was evaluated and how the clinical applicability of results was interpreted. The papers supported our anecdotal impression that pathologists usually assess IOV using Cohen's or Fleiss' kappa statistics and interpret the results using some variation of the scale proposed by Landis and Koch. The papers did not cite or propose specific guidelines to comment on the clinical applicability of results. The solutions proposed to decrease IOV included the development of better diagnostic criteria and additional educational efforts, but the possibility that the entities themselves represented a continuum of morphologic findings rather than distinct diagnostic categories was not considered in any of the studies. A dataset from a previous study of IOV reported by Thunnissen et al. was recalculated to estimate percent agreement among 19 international lung pathologists for the diagnosis of 74 challenging lung neuroendocrine neoplasms. Kappa scores and diagnostic sensitivity, specificity, positive and negative predictive values were calculated using the majority consensus diagnosis for each case as the gold reference diagnosis for that case. Diagnostic specificity estimates among multiple pathologists were > 90%, although kappa scores were considerably more variable. We explain why kappa scores are of limited clinical applicability in pathology and propose the use of positive and negative percent agreement and diagnostic specificity against a gold reference diagnosis to evaluate IOV among two and multiple raters, respectively., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?
- Author
-
Hu Y, Taylor-Harding B, Raz Y, Haro M, Recouvreux MS, Taylan E, Lester J, Millstein J, Walts AE, Karlan BY, and Orsulic S
- Abstract
Primary ovarian high-grade serous carcinoma (HGSC) has been classified into 4 molecular subtypes: Immunoreactive, Proliferative, Differentiated, and Mesenchymal (Mes), of which the Mes subtype (Mes-HGSC) is associated with the worst clinical outcomes. We propose that Mes-HGSC comprise clusters of cancer and associated stromal cells that detached from tumors in the upper abdomen/omentum and disseminated in the peritoneal cavity, including to the ovary. Using comparative analyses of multiple transcriptomic data sets, we provide the following evidence that the phenotype of Mes-HGSC matches the phenotype of tumors in the upper abdomen/omentum: (1) irrespective of the primary ovarian HGSC molecular subtype, matched upper abdominal/omental metastases were typically of the Mes subtype, (2) the Mes subtype was present at the ovarian site only in patients with concurrent upper abdominal/omental metastases and not in those with HGSC confined to the ovary, and (3) ovarian Mes-HGSC had an expression profile characteristic of stromal cells in the upper abdominal/omental metastases. We suggest that ovarian Mes-HGSC signifies advanced intraperitoneal tumor dissemination to the ovary rather than a subtype of primary ovarian HGSC. This is consistent with the presence of upper abdominal/omental disease, suboptimal debulking, and worst survival previously reported in patients with ovarian Mes-HGSC compared to other molecular subtypes., (Copyright © 2020 Hu, Taylor-Harding, Raz, Haro, Recouvreux, Taylan, Lester, Millstein, Walts, Karlan and Orsulic.)
- Published
- 2020
- Full Text
- View/download PDF
28. Prognosis in pathology: Are we "prognosticating" or only establishing correlations between independent variables and survival? A study with various analytics cautions about the overinterpretation of statistical results.
- Author
-
Marchevsky AM, Diniz MA, Manzoor D, and Walts AE
- Subjects
- Humans, Pathology, Clinical standards, Prognosis, Carcinoid Tumor mortality, Kaplan-Meier Estimate, Lung Neoplasms mortality, Neural Networks, Computer, Pathology, Clinical methods
- Abstract
Survival data from 225 patients with resected pulmonary typical carcinoids were analyzed with Kaplan-Meier statistics (K-M) and "deep learning" methods to illustrate the difference between establishing "correlations" and "prognostications". Cases were stratified into G1 and G2 classes using a ≤5% Ki-67% cut-point. Overall survival, number of patients at risk and 95% confidence intervals (CI) were estimated for the two classes. Seven neural network models (NN) were developed with GMDH Shell 3.8.2 and Statgraphics Centurion 18.1 software, using variable prior probabilities and different numbers of training vs testing cases. The NNs used age, sex, and pTNM, G1 and G2 as input neurons and "alive" and "dead" as output neurons. Areas under the curve (AUC) and other performance measures were evaluated for all models. Log-rank test showed a significant difference in overall survival between G1 and G2 (p < 0.001). However, 95% CI estimates showed considerable variability in survival at different time intervals. Including the number of patients at risk at different time intervals showed that most G2 patients had been censored by 100 weeks. The NN models provided variable "prognostications", with AUC ranging from 0.5 to 1 and variability in the sensitivity, specificity, and other performance measures. The results illustrate the limitations of survival statistics and NNs in predicting the prognosis of individual patients. The need for pathologists not to overinterpret the finding of significant correlations as "prognostic" or "predictive" for individual patients is discussed., Competing Interests: Declaration of competing interest None of the authors had financial and/or personal relationships with other people or organizations that could had inappropriately influenced (biased) their work., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
29. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.
- Author
-
Marchevsky AM, Khoor A, Walts AE, Nicholson AG, Zhang YZ, Roggli V, Carney J, Roden AC, Tazelaar HD, Larsen BT, LeStang N, Chirieac LR, Klebe S, Tsao MS, De Perrot M, Pierre A, Hwang DM, Hung YP, Mino-Kenudson M, Travis W, Sauter J, Beasley MB, and Galateau-Sallé F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, Child, Diagnosis, Differential, Evidence-Based Medicine, Female, Humans, Male, Mesothelioma, Malignant diagnostic imaging, Mesothelioma, Malignant mortality, Mesothelioma, Malignant therapy, Middle Aged, Pleural Neoplasms diagnostic imaging, Pleural Neoplasms mortality, Pleural Neoplasms therapy, Predictive Value of Tests, Prognosis, Solitary Fibrous Tumor, Pleural diagnostic imaging, Solitary Fibrous Tumor, Pleural mortality, Solitary Fibrous Tumor, Pleural therapy, Tumor Burden, Young Adult, Mesothelioma, Malignant pathology, Pleural Neoplasms pathology, Solitary Fibrous Tumor, Pleural pathology
- Abstract
Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as "mesothelioma", LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.
- Published
- 2020
- Full Text
- View/download PDF
30. Pathology in the era of "Personalized Medicine": The need to learn how to integrate multivariate immunohistochemical and "omics" data with clinicopathologic information in a clinically relevant way".
- Author
-
Marchevsky AM, Walts AE, and Wick MR
- Subjects
- Early Diagnosis, Evidence-Based Medicine methods, Humans, Knowledge, Laboratories statistics & numerical data, Neoplasms pathology, Pathologists statistics & numerical data, Precision Medicine standards, Research Design standards, Genomics methods, Immunohistochemistry methods, Neoplasms metabolism, Neoplasms therapy, Precision Medicine methods
- Abstract
"Personalized medicine" has been proposed as a new paradigm for patient care that, based on the integration of genomics and other "omics" data with clinical and other multidisciplinary information, promises early disease detection, improved outcomes and reduced side effects to therapies. Pathologists have become important participants in this new approach as the guardians of tissues and experts in the performance of molecular and other laboratory tests. Large amounts of new laboratory data in multiple neoplasms and other entities are being reported but there has been limited discussion about how best to evaluate the clinical significance of this information and how to integrate it into currently available diagnostic and therapeutic modalities. This article introduces a variety of epistemological problems presented by the "personalized medicine" paradigm and briefly discusses various topics that will be evaluated in further detail in future articles of this new series on Evidence-Based Pathology., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
31. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
- Author
-
Bose S, Sacks W, and Walts AE
- Subjects
- Biopsy, Fine-Needle, Clinical Decision-Making, Diagnosis, Differential, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Humans, Phenotype, Predictive Value of Tests, Prognosis, Reproducibility of Results, Thyroid Neoplasms pathology, Thyroid Neoplasms therapy, Thyroid Nodule pathology, Thyroid Nodule therapy, Transcriptome, Biomarkers, Tumor genetics, Molecular Diagnostic Techniques, Thyroid Neoplasms genetics, Thyroid Nodule genetics
- Abstract
Fine needle aspiration biopsy (FNAB) and ultrasonography are the most common modalities for the diagnosis and follow up of thyroid nodules. FNAB is able to distinguish benign from malignant nodules with high sensitivity and specificity; however, 20% to 30% of nodules are diagnosed as indeterminate with a risk of malignancy varying from 10% to 75% based on the 2017 revision of the Bethesda System for Reporting Thyroid Cytopathology. Molecular tests are being increasingly used to triage this group of nodules. Several molecular tests are commercially available and newer upgrades are being developed to either "rule in" or "rule out" malignancy with greater accuracy. The Afirma gene expression classifier and its recent upgrade (the Afirma gene sequencing classifier), Thryoseq v2, a next generation sequencing test and its recent upgrade (the v3), RosettaGX Reveal based on microRNA alterations, and ThyGenX/ThyraMIR, a combination test, are currently on the market. Familiarity with these tests, their performance, and postvalidation publications will enable appropriate test selection and improve triage of patients for appropriate therapy. The underlying rate of malignancy at different institutions and the interobserver variability in cytologic and histologic diagnosis of thyroid lesions are important factors that impact the performance of the various molecular tests.
- Published
- 2019
- Full Text
- View/download PDF
32. Convolutional neural networks can accurately distinguish four histologic growth patterns of lung adenocarcinoma in digital slides.
- Author
-
Gertych A, Swiderska-Chadaj Z, Ma Z, Ing N, Markiewicz T, Cierniak S, Salemi H, Guzman S, Walts AE, and Knudsen BS
- Subjects
- Adenocarcinoma pathology, Data Accuracy, Humans, Lung Neoplasms pathology, Neural Networks, Computer, Prognosis, Adenocarcinoma of Lung diagnostic imaging, Adenocarcinoma of Lung pathology, Image Processing, Computer-Assisted methods
- Abstract
During the diagnostic workup of lung adenocarcinomas (LAC), pathologists evaluate distinct histological tumor growth patterns. The percentage of each pattern on multiple slides bears prognostic significance. To assist with the quantification of growth patterns, we constructed a pipeline equipped with a convolutional neural network (CNN) and soft-voting as the decision function to recognize solid, micropapillary, acinar, and cribriform growth patterns, and non-tumor areas. Slides of primary LAC were obtained from Cedars-Sinai Medical Center (CSMC), the Military Institute of Medicine in Warsaw and the TCGA portal. Several CNN models trained with 19,924 image tiles extracted from 78 slides (MIMW and CSMC) were evaluated on 128 test slides from the three sites by F1-score and accuracy using manual tumor annotations by pathologist. The best CNN yielded F1-scores of 0.91 (solid), 0.76 (micropapillary), 0.74 (acinar), 0.6 (cribriform), and 0.96 (non-tumor) respectively. The overall accuracy of distinguishing the five tissue classes was 89.24%. Slide-based accuracy in the CSMC set (88.5%) was significantly better (p < 2.3E-4) than the accuracy in the MIMW (84.2%) and TCGA (84%) sets due to superior slide quality. Our model can work side-by-side with a pathologist to accurately quantify the percentages of growth patterns in tumors with mixed LAC patterns.
- Published
- 2019
- Full Text
- View/download PDF
33. Carcinoid tumors of the thymus and Cushing's syndrome: Clinicopathologic features and current best evidence regarding the cell of origin of these unusual neoplasms.
- Author
-
Walts AE, Frye J, Engman DM, and Marchevsky AM
- Subjects
- Adrenocorticotropic Hormone metabolism, Adult, Aged, Carcinoid Tumor complications, Corticotropin-Releasing Hormone metabolism, Female, Humans, Male, Middle Aged, Neuroendocrine Cells metabolism, Thymus Neoplasms complications, Young Adult, Carcinoid Tumor pathology, Cushing Syndrome etiology, Neuroendocrine Cells pathology, Thymus Neoplasms pathology
- Abstract
It is uncertain whether thymic neuroendocrine tumors (NET) associated with Cushing's syndrome (CS) produce corticotropin-releasing hormone (CRH) and adrenocorticotropin hormone (ACTH) and whether the thymus contains ACTH and/or CRH cells that could originate NET. The clinicopathologic features of 5 typical (TC) and 6 atypical carcinoids (ATC), 10 additional non-neoplastic thymi, 6 adrenal glands with bilateral nodular hyperplasia and 8 adrenal cortical adenomas were reviewed. Representative slides were immunostained for ACTH and CRH. Four (36.4%) of the 11 patients had CS. The incidence of Masaoka stage IV was higher (p < 0.0001) in patients with ATC than TC. Only 2 (18.1%) of the 11 patients were alive at follow-up. Ten NET were CRH immunoreactive and 6 were ACTH immunoreactive. Thymic NET with CS exhibited stronger immunoreactivity for ACTH and CRH than those without CS. Non-neoplastic thymi exhibited scattered ACTH and CRH immunoreactive cells. Normal adrenal cortex and glands with bilateral nodular hyperplasia showed diffuse CRH immunoreactivity while adrenal adenomas showed no or only focal CRH immunoreactivity. Literature review showed no association between thymic NET and adrenal adenomas. The thymus contains CRH and ACTH immunoreactive cells that are probably the origin of thymic NET. Neoplasms associated with CS exhibit strong immunoreactivity for both hormones, suggesting that CRH probably plays a role in the pathogenesis of CS. As adrenals with bilateral nodular hyperplasia exhibit diffuse CRH immunoreactivity and adrenal cortical adenomas either lack this finding or show few immunoreactive cells, this marker may be useful to distinguish these lesions., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
- Author
-
Walts AE, Mirocha JM, and Bose S
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms mortality, Female, Humans, Lymph Nodes pathology, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Algorithms, Breast Neoplasms pathology, Neoplasm Recurrence, Local genetics, Receptors, Estrogen metabolism, Reverse Transcriptase Polymerase Chain Reaction methods
- Abstract
Data from pathology reports of estrogen receptor positive (ER+) breast cancers with Ki67 < 14% (luminal-A; n = 128) and Ki67 ≥ 14% (luminal-B; n = 100) were entered into the automatic recurrence score (RS) calculator accessible at the University of Pittsburgh Department of Pathology website. Using RS obtained with Magee equations #1 and #3, an average modified Magee recurrence score (AMM RS) was calculated for each tumor. The AMM RS and the Oncotype DX RS (Onco RS) were compared per tumor and associated with follow-up. AMM RS and Onco RS agreed in 64.9% (148 of 228) breast cancers (70.3% luminal-A and 58% luminal-B). There was only one two-step (low risk by Onco/high risk by AMM) RS disagreement. This luminal-B patient is alive without recurrence and free of tumor at 46 months postdiagnosis. Low-risk/intermediate-risk disagreements comprised 94.7% (36 of 38) and 69% (29 of 42) of the RS disagreements in the luminal-A and luminal-B groups, respectively (P = 0.004). In luminal-A, there were only two intermediate/high-risk disagreements; both high-risk ratings were by Onco RS. In luminal-B, there were 12 intermediate/high-risk disagreements; 11 of the high-risk ratings were by Onco RS. 100% (3 of 3) luminal-A tumors and 75% (6 of 8) luminal-B tumors that were high risk by AMM RS were also high risk by Onco RS. Eight tumors recurred and/or metastasized. AMM RS and Onco RS disagreed in only two of these eight tumors. The high percentage of tumors scored as intermediate risk (50% by AMM RS and 39% by Onco RS) is a major limitation of both scoring algorithms., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
35. A retrospective analysis of the performance of the RosettaGX ® Reveal™ thyroid miRNA and the Afirma Gene Expression Classifiers in a cohort of cytologically indeterminate thyroid nodules.
- Author
-
Walts AE, Sacks WL, Wu HH, Randolph ML, and Bose S
- Subjects
- Biomarkers, Tumor metabolism, Biomarkers, Tumor standards, Humans, MicroRNAs metabolism, Reproducibility of Results, Sensitivity and Specificity, Thyroid Nodule classification, Thyroid Nodule genetics, Thyroid Nodule metabolism, Biomarkers, Tumor genetics, MicroRNAs genetics, Reagent Kits, Diagnostic standards, Thyroid Nodule pathology
- Abstract
Background: Molecular tests are increasingly used to triage cytologically indeterminate thyroid nodules for surgery and/or follow-up. We retrospectively compared the performance of the Afirma Gene Expression Classifier (AGEC) with that of the more recently developed RosettaGX
® Reveal™ miRNA Classifier (Reveal) in a cohort of Bethesda III-V thyroid FNAs with surgical follow-up., Design: Eighty-one samples (54 Bethesda III, 26 Bethesda IV, 1 Bethesda V) with available AGEC (74 AGEC-SUSP and 7 AGEC-BENIGN) and surgical pathology results were studied from three academic centers. Reveal was performed in a blinded fashion., Results: The final diagnoses were benign/NIFTP (n = 63) and malignant (n = 18). The overall "correct" rate was 64.2% for Reveal and 28.4% for AGEC (P = 1.4e-6). The specificity of Reveal was 60.3%, compared with 9.5% for AGEC (P = 2.1e-9). Among the 18 malignant cases, 77.8% and 94.4% were correctly classified as suspicious by Reveal and AGEC, respectively (P = 0.2). In the FLUS and the FN group, the specificity of AGEC was lower than the specificity of Reveal. Whether the 7 NIFTP in our study were considered benign or malignant, specificity and PPV of Reveal were higher than those of AGEC. Reveal also outperformed AGEC in correctly classifying the 26 benign Hürthle lesions studied (P = 7.6e-5)., Conclusion: Reveal outperformed AGEC in this cohort, whether NIFTP is considered benign or malignant, and in Hürthle lesions. Reveal has the potential to reduce the number of unnecessary resections in patients with indeterminate thyroid cytology. Based on our findings and the practical advantages offered by Reveal methodology, large prospective studies are warranted. Diagn. Cytopathol., (© 2018 Wiley Periodicals, Inc.)- Published
- 2018
- Full Text
- View/download PDF
36. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.
- Author
-
Marchevsky AM, Hendifar A, and Walts AE
- Subjects
- Adult, Aged, Biomarkers, Tumor analysis, Carcinoid Tumor classification, Carcinoid Tumor diagnosis, Carcinoid Tumor mortality, Carcinoid Tumor pathology, Female, Humans, Lung Neoplasms diagnosis, Lung Neoplasms mortality, Male, Middle Aged, Neuroendocrine Tumors classification, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors mortality, Practice Patterns, Physicians', Prognosis, Surveys and Questionnaires, Ki-67 Antigen analysis, Lung Neoplasms pathology, Medical Oncology methods, Neoplasm Grading methods, Neuroendocrine Tumors pathology
- Abstract
Although Ki-67 labeling index (Ki-67%) is not a diagnostic or grading criterion in the World Health Organization classification of pulmonary carcinoid tumor, oncologists often request this test. A survey was administered at a North American Society for Neuroendocrine Tumors meeting to understand how Ki-67% is used in oncologic practices. A systematic literature review was performed to gather best evidence regarding the use of Ki-67%. Consecutive pulmonary carcinoids were stratified into pulmonary typical carcinoids with Ki-67% <5% (group A, n = 187), typical carcinoids with Ki-67% ≥5% (group B, n = 38) and atypical carcinoids irrespective of Ki-67% (group C, n = 31). Overall survival, progression-free survival, recurrence proportions and time to recurrence were compared, by group, using the log-rank test, chi-square statistics and ANOVA, respectively. Our survey confirmed that Ki-67% is frequently used by specialists caring for these patients. Ki-67% of 1-7% significantly correlated with overall survival in the literature but we found no information about Ki-67% cut-off values that would accurately distinguish pulmonary typical from atypical carcinoids or estimate the prognosis of patients stratified by World Health Organization diagnosis and Ki-67% cut-off. Overall survival was significantly different in our 3 patient groups (p < 0.001), with survival probabilities decreasing from groups A to C. Progression-free survival was significantly longer in group A than B (p < 0.007). Our results support the concept that by combining World Health Organization diagnosis and Ki-67%, pulmonary carcinoids can be stratified into 3 grades: G1 (typical carcinoids with Ki-67% <5), G2 (typical carcinoids with Ki-67% ≥5%) and G3 (atypical carcinoids) with different prognoses.
- Published
- 2018
- Full Text
- View/download PDF
37. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
- Author
-
Astvatsaturyan K, Yue Y, Walts AE, and Bose S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Gene Expression Regulation, Neoplastic, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Grading, Prognosis, Triple Negative Breast Neoplasms pathology, Tumor Burden, Receptors, Androgen metabolism, Triple Negative Breast Neoplasms diagnosis, Triple Negative Breast Neoplasms metabolism
- Abstract
Introduction: Overexpression of the androgen receptor (AR) characterizes a distinct molecular subset of triple negative breast carcinomas (TNBC). The role of AR as a prognostic/predictive biomarker in TNBC is controversial, but increasing evidence suggests that this subset may respond to therapeutic agents targeting AR. Evaluation of AR has not been standardized, and criteria for selection of patients for antiandrogen therapy remain controversial. In this study we determine the appropriate threshold of AR immunoreactivity to define AR positive (AR+) TNBC, describe the clinicopathologic features of AR+ TNBC, and discuss the utility of AR positivity as a prognostic and predictive marker in TNBC., Materials and Methods: 135 invasive TNBC processed in accordance with ASCO/CAP guidelines, were immunostained for AR. Clinicopathologic features of AR+ TNBC were analyzed and compared to AR negative (AR-) TNBC. Patients' age, tumor size, tumor grade, lymph node status, proliferation rate, immunopositivity for EGFR, CK5/6, Ki-67, and disease free survival (DFS) were evaluated statistically., Results: A 1% cutpoint was confirmed as the appropriate threshold for AR positivity. Using this cutpoint 41% of 135 TNBC were AR+. AR+ TNBC occurred in older women, were larger, had lower mean proliferation rate and increased incidence of axillary metastasis than AR- TNBC. 76% of TNBC with apocrine morphology were AR+. A subset of AR+TNBC expressed basal markers (EGFR and CK5/6). A prognostic model was created., Summary: AR identifies a heterogeneous group of TNBC. Additional evaluation of EGFR expression allowed us to stratify TNBCs into 3 risk groups with significant differences in DFS and therapeutic implications: low-risk (AR+ EGFR-) which represents the LAR molecular subtype with the best prognosis and may benefit the most from anti-androgen therapies; high-risk (AR- EGFR+) which represents the basal molecular subtype with the worst prognosis and may benefit the most from chemotherapy regimens; intermediate-risk (AR+EGFR+ and AR-EGFR-) TNBC with an intermediate prognosis. Prospective trials are required to further validate this prognostic and predictive grouping., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
38. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
- Author
-
Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, and Husain AN
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Nucleus pathology, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Male, Mesothelioma mortality, Mesothelioma, Malignant, Middle Aged, Pleural Neoplasms mortality, Prognosis, Lung Neoplasms pathology, Mesothelioma pathology, Necrosis pathology, Neoplasm Grading methods, Pleural Neoplasms pathology
- Abstract
A recently described nuclear grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The current study was undertaken to validate the grading system and to identify additional prognostic factors. We analyzed cases of epithelioid malignant pleural mesothelioma from 17 institutions across the globe from 1998 to 2014. Nuclear grade was computed combining nuclear atypia and mitotic count into a grade of I-III using the published system. Nuclear grade was assessed by one pathologist for three institutions, the remaining were scored independently. The presence or absence of necrosis and predominant growth pattern were also evaluated. Two additional scoring systems were evaluated, one combining nuclear grade and necrosis and the other mitotic count and necrosis. Median overall survival was the primary endpoint. A total of 776 cases were identified including 301 (39%) nuclear grade I tumors, 354 (45%) grade II tumors and 121 (16%) grade III tumors. The overall survival was 16 months, and correlated independently with age (P=0.006), sex (0.015), necrosis (0.030), mitotic count (0.001), nuclear atypia (0.009), nuclear grade (<0.0001), and mitosis and necrosis score (<0.0001). The addition of necrosis to nuclear grade further stratified overall survival, allowing classification of epithelioid malignant pleural mesothelioma into four distinct prognostic groups: nuclear grade I tumors without necrosis (29 months), nuclear grade I tumors with necrosis and grade II tumors without necrosis (16 months), nuclear grade II tumors with necrosis (10 months) and nuclear grade III tumors (8 months). The mitosis-necrosis score stratified patients by survival, but not as well as the combination of necrosis and nuclear grade. This study confirms that nuclear grade predicts survival in epithelioid malignant pleural mesothelioma, identifies necrosis as factor that further stratifies overall survival, and validates the grading system across multiple institutions and among both biopsy and resection specimens. An alternative scoring system, the mitosis-necrosis score is also proposed.
- Published
- 2018
- Full Text
- View/download PDF
39. Current Evidence Does Not Warrant Frozen Section Evaluation for the Presence of Tumor Spread Through Alveolar Spaces.
- Author
-
Walts AE and Marchevsky AM
- Subjects
- Adenocarcinoma surgery, Adenocarcinoma of Lung, Aged, Aged, 80 and over, Female, Humans, Intraoperative Period, Lung Neoplasms surgery, Male, Middle Aged, Neoplasm Invasiveness diagnosis, Neoplasm Invasiveness pathology, Predictive Value of Tests, Prognosis, Thoracic Surgery, Video-Assisted, Thoracotomy, Adenocarcinoma diagnosis, Adenocarcinoma pathology, Frozen Sections statistics & numerical data, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Pulmonary Alveoli pathology
- Abstract
Context: - Tumor spread through alveolar spaces (STAS) has been correlated with unfavorable prognosis in lung adenocarcinomas treated with sublobar resection, but it is unknown whether STAS can be reliably identified in frozen section (FS) to help stratify patients for lobectomy or sublobar resection., Objective: - To evaluate STAS in FS., Design: - Tumor spread through alveolar spaces was evaluated in hematoxylin-eosin-stained FS, FS control slides, and all additional slides with lung tissue adjacent to tumor (AdLT) from 48 pT1-2 adenocarcinomas operated on using video-assisted thoracotomy (n = 25) or open thoracotomy (n = 23). The samples included lobectomies (n = 27) and sublobar resections (n = 21). The STAS incidences were compared by FS versus FS control versus AdLT, video-assisted thoracotomy versus open thoracotomy, and lobectomy versus sublobar resection. Sensitivity, specificity, and positive and negative predictive values of STAS
+ findings were calculated. The literature was queried for best evidence regarding incidence and predictive value of STAS in FS., Results: - Tumor spread through alveolar spaces positivity was identified in 46 of 48 cases (95.8%), including 23 FS (47.9%), 32 FS control (66.7%), and 43 AdLT (89.6%). The STAS incidence was significantly higher in AdLT than in FS or FS control. Only 2 of the 25 cases that were STAS- in FS were true negatives. Frozen section sensitivity to detect STAS positivity was 50%, with a 100% positive predictive value and 8% negative predictive value. Systematic literature review identified no evidence regarding STAS identification in FS., Conclusions: - The sensitivity and negative predictive value of FS for STAS detection are unacceptably low. There are insufficient data to support intraoperative detection of STAS as a useful predictive feature to help stratify patients for lobectomy or sublobar resections.- Published
- 2018
- Full Text
- View/download PDF
40. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
- Author
-
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, and Wick MR
- Subjects
- Adenocarcinoma metabolism, Biomarkers, Tumor metabolism, Consensus, Cytodiagnosis methods, Diagnosis, Differential, Humans, Immunohistochemistry, Lung chemistry, Lung Neoplasms metabolism, Mesothelioma metabolism, Public Opinion, Adenocarcinoma diagnosis, Lung pathology, Lung Neoplasms diagnosis, Mesothelioma diagnosis
- Abstract
Context: - Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose., Objective: - To provide updated, practical guidelines for the pathologic diagnosis of MM., Data Sources: - Pathologists involved in the International Mesothelioma Interest Group and others with an interest and expertise in the field contributed to this update. Reference material included up-to-date, peer-reviewed publications and textbooks., Conclusions: - There was discussion and consensus opinion regarding guidelines for (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) recognition of the key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid MM, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels employed is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Depending on the morphology, immunohistochemical panels should contain both positive and negative markers for mesothelial differentiation and for lesions considered in the differential diagnosis. Immunohistochemical markers should have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic and membranous markers). Selected molecular markers are now being used to distinguish benign from malignant mesothelial proliferations. These guidelines are meant to be a practical diagnostic reference for the pathologist; however, some new pathologic predictors of prognosis and response to therapy are also included.
- Published
- 2018
- Full Text
- View/download PDF
41. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.
- Author
-
Patel SB, Kadi W, Walts AE, Marchevsky AM, Pao A, Aguiluz A, Mudalige T, Liu Z, Deng N, and Lopategui J
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Adenocarcinoma of Lung, Aged, Diagnosis, Differential, ErbB Receptors genetics, Female, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Mutation, Neoplasm Metastasis genetics, Neoplasm Metastasis pathology, Neoplasm Proteins genetics, Neoplasms, Multiple Primary genetics, Neoplasms, Multiple Primary pathology, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Adenocarcinoma diagnosis, High-Throughput Nucleotide Sequencing, Lung Neoplasms diagnosis, Neoplasm Metastasis diagnosis, Neoplasms, Multiple Primary diagnosis
- Abstract
Distinguishing between multiple lung primary tumors and intrapulmonary metastases is imperative for accurate staging. The American Joint Committee on Cancer (AJCC) criteria are routinely used for this purpose but can yield equivocal conclusions. This study evaluated whether next-generation sequencing (NGS) using the 50-gene AmpliSeq Cancer Hotspot Panel version 2 can help facilitate this distinction. NGS was performed on known primary-metastatic pairs (8 patients) and multiple lung adenocarcinomas (11 patients). Primary-metastatic pairs had high mutational concordance. Seven pairs shared mutations, and 1 was concordant for having no mutations. Driver mutations in KRAS (n = 4), EGFR (n = 2), and BRAF (n = 1) were always concordant. Multiple lung tumors from 3 patients were completely concordant and predicted by NGS to be intrapulmonary metastases, whereas 8 had completely discordant mutations and were predicted to be independent primary tumors. The NGS prediction correlated with the AJCC (eighth edition) prediction in all patients for whom the latter was unequivocal (8 of 11). Furthermore, it separated patients by overall survival. Patients with predicted multiple independent primary tumors by NGS had better survival than those with distant metastases (P = 0.016, log-rank test), whereas those with predicted intrapulmonary metastases had no difference (P = 0.527). With further validation, the 50-gene panel has the potential to serve as an adjunct to the AJCC criteria., (Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
42. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
- Author
-
Zakhour M, Cohen JG, Gibson A, Walts AE, Karimian B, Baltayan A, Aoyama C, Garcia L, Dhaliwal SK, Elashoff D, Amneus M, and Walsh C
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Adult, Endometrial Hyperplasia genetics, Endometrial Hyperplasia pathology, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, Humans, Immunohistochemistry, Middle Aged, Adenocarcinoma drug therapy, DNA Mismatch Repair, Endometrial Hyperplasia drug therapy, Endometrial Neoplasms drug therapy, Progestins therapeutic use
- Abstract
Objective: To report the response to progestin therapy in young women with endometrial complex atypical hyperplasia (CAH) or FIGO grade 1 endometrial adenocarcinoma (FIGO 1 EAC) based on clinicopathologic features, including abnormal DNA mismatch repair (MMR) by immunohistochemistry (IHC)., Design: Consecutive case series., Setting: Olive View-UCLA Medical Center in Sylmar, CA, USA, and Cedars-Sinai Medical Center in Los Angeles, CA, USA., Population: Women ≤55 years old with CAH or FIGO 1 EAC., Methods: Response to progestin therapy in 84 consecutive patients was assessed based on clinicopathologic factors, including age, body mass index (BMI), initial histology, and IHC staining for MMR proteins., Main Outcome Measures: Rates of abnormal MMR protein expression and response to progestin therapy were determined., Results: Six (7%) patients had abnormal IHC staining, of whom five (83%) had FIGO 1 EAC at initial diagnosis. Following progestin treatment, none of the endometrial lesions in patients with abnormal IHC for MMR proteins had resolution of hyperplasia or malignancy, in contrast to 41 (53%) with normal staining (P = 0.028). Age ≤40 years and initial lesion (CAH versus FIGO 1 EAC) were predictors of response to progestin; BMI was not., Conclusions: In this cohort, 7% of women ≤55 years of age with CAH or FIGO 1 EAC had loss of MMR proteins by IHC. These patients had a higher incidence of invasive cancer and a lower incidence of resolution with progestin therapy., Tweetable Abstract: Abnormal MMR protein expression predicts poor response to progestins in young women with CAH or FIGO 1 EAC., (© 2017 Royal College of Obstetricians and Gynaecologists.)
- Published
- 2017
- Full Text
- View/download PDF
43. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
- Author
-
Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, Karlan BY, Mackman N, and Walsh CS
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Ovarian Epithelial, Case-Control Studies, Enzyme Multiplied Immunoassay Technique, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Staging, Survival Analysis, Thromboplastin biosynthesis, Neoplasms, Glandular and Epithelial blood, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms blood, Ovarian Neoplasms pathology, Thromboplastin metabolism, Venous Thrombosis blood, Venous Thrombosis pathology
- Abstract
Objective: Ovarian clear cell carcinoma (OCCC) and high grade serous ovarian cancer (HGSOC) are associated with the highest risk of VTE among patients with epithelial ovarian cancer (EOC). Tissue factor (TF) is a transmembrane glycoprotein which can trigger thrombosis. We sought to evaluate if there is an association between VTE and tumor expression of tissue factor (TF), plasma TF, and microvesicle TF (MV TF) activity in this high-risk population., Methods: We performed a case-control study of OCCC and HGSOC patients with and without VTE. 105 patients who underwent surgery at a tertiary care center between January 1995 and October 2013 were included. Plasma TF was measured with an enzyme-linked immunosorbent assay. A TF-dependent Factor Xa generation assay was used to measure MV TF activity. Immunohistochemical (IHC) analysis was performed to evaluate tumor expression of TF., Results: 35 women with OCCC or HGSOC diagnosed with VTE within 9months of surgery were included in the case group. Those with VTE had a worse OS, p<0.0001, with a greater than three-fold increase in risk of death, HR 3.33 (CI 1.75-6.35). There was no significant difference in median plasma TF level or MV TF activity level between patients with and without VTE. OCCC patients had greater expression of TF in their tumors than patients with HGSOC, p<0.0001., Conclusions: TFMV activity and plasma TF level were not predictive of VTE in this patient population. Given the extensive expression of TF in OCCC tumors, it is unlikely IHC expression will be useful in risk stratification for VTE in this population., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. Evidence-based pathology in its second decade: toward probabilistic cognitive computing.
- Author
-
Marchevsky AM, Walts AE, and Wick MR
- Subjects
- Area Under Curve, Carcinoid Tumor chemistry, Carcinoid Tumor mortality, Cell Proliferation, Diagnosis, Computer-Assisted history, Evidence-Based Medicine history, History, 21st Century, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Ki-67 Antigen analysis, Lung Neoplasms chemistry, Lung Neoplasms mortality, Models, Statistical, Pathology history, Predictive Value of Tests, Prognosis, Proportional Hazards Models, ROC Curve, Reproducibility of Results, Software, Time Factors, Carcinoid Tumor pathology, Data Mining history, Diagnosis, Computer-Assisted methods, Evidence-Based Medicine methods, Lung Neoplasms pathology, Pathology methods, Probability Learning
- Abstract
Evidence-based pathology advocates using a combination of best available data ("evidence") from the literature and personal experience for the diagnosis, estimation of prognosis, and assessment of other variables that impact individual patient care. Evidence-based pathology relies on systematic reviews of the literature, evaluation of the quality of evidence as categorized by evidence levels and statistical tools such as meta-analyses, estimates of probabilities and odds, and others. However, it is well known that previously "statistically significant" information usually does not accurately forecast the future for individual patients. There is great interest in "cognitive computing" in which "data mining" is combined with "predictive analytics" designed to forecast future events and estimate the strength of those predictions. This study demonstrates the use of IBM Watson Analytics software to evaluate and predict the prognosis of 101 patients with typical and atypical pulmonary carcinoid tumors in which Ki-67 indices have been determined. The results obtained with this system are compared with those previously reported using "routine" statistical software and the help of a professional statistician. IBM Watson Analytics interactively provides statistical results that are comparable to those obtained with routine statistical tools but much more rapidly, with considerably less effort and with interactive graphics that are intuitively easy to apply. It also enables analysis of natural language variables and yields detailed survival predictions for patient subgroups selected by the user. Potential applications of this tool and basic concepts of cognitive computing are discussed., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
45. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
- Author
-
Marchevsky AM and Walts AE
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, CD4-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes pathology, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Child, Child, Preschool, Female, Humans, Immunohistochemistry, Infant, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Predictive Value of Tests, Thymoma pathology, Thymoma surgery, Thymus Hyperplasia pathology, Thymus Hyperplasia surgery, Thymus Neoplasms pathology, Thymus Neoplasms surgery, Young Adult, B7-H1 Antigen analysis, Biomarkers, Tumor analysis, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Carcinoma, Squamous Cell immunology, Lymphocytes, Tumor-Infiltrating immunology, Programmed Cell Death 1 Receptor analysis, Thymoma immunology, Thymus Hyperplasia immunology, Thymus Neoplasms immunology
- Abstract
The checkpoint protein programmed cell death ligand-1 protein (PD-L1) binds to its receptor (PD-1) activating the PD-L1/PD-1 pathway, an important therapeutic target. There is limited information regarding PD-L1 and PD-1 expression in thymic lesions. Sections from nonneoplastic thymi (n = 20), thymomas World Health Organization types A, AB, B1, B2, and B3 (n = 38) and thymic squamous cell carcinoma (n = 8) were stained for PD-L1 (clone SP142; Spring BioScience), PD-1 (MRQ22; Cell Marque), CD4 (clone SPO32; Cell Marque), and CD8 (JCB117; Ventana). Immunoreactivity for each antibody was classified as focal or diffuse and scored as follows: 0, negative; 1%-5%, 1+; 6%-20%, 2+; and >20%, 3+. The proportions of cases expressing PD-L1, PD-1, CD4, and C8 at score ≥1+ were compared by diagnosis, using χ
2 statistics. PD-L1 was expressed in 90% of nonneoplastic thymi, 92% of thymomas, and 50% of carcinomas, with significantly higher scores (P < .01) in B2 and B3 thymomas and carcinomas than in AB and B1 thymomas; PD-L1 was diffuse in most B2 and B3 thymomas and focal in carcinomas. PD-1 was focally expressed, and mostly with scores 1+, in 55% of nonneoplastic thymi, 63% of thymomas, and 37.5% of carcinomas. CD4+ and CD8+ cells were diffusely distributed with scores 3+ in all lesions other than B3 thymomas and carcinomas. The latter showed CD4+ cells mostly at the interface between neoplastic cells and stroma. PD-L1 and PD-1 are not expressed in similar locations and cellular proportions in thymic lesions, raising a question as to whether the PD-L1/PD-1 pathway is an actionable therapeutic target in these lesions., (Copyright © 2016 Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
46. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets.
- Author
-
Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, and Orsulic S
- Subjects
- Actins metabolism, Biomarkers, Tumor metabolism, Cancer-Associated Fibroblasts pathology, Carcinoma, Ovarian Epithelial, Cell Line, Tumor, Coculture Techniques, Collagen Type I metabolism, Collagen Type I, alpha 1 Chain, Databases, Genetic, Disease-Free Survival, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Myofibroblasts pathology, Neoplasm Grading, Neoplasm Staging, Neoplasms, Glandular and Epithelial metabolism, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Time Factors, Tumor Microenvironment, Biomarkers, Tumor genetics, Cancer-Associated Fibroblasts metabolism, Collagen Type I genetics, Myofibroblasts metabolism, Neoplasms, Glandular and Epithelial genetics, Ovarian Neoplasms genetics, Transcriptome
- Abstract
Although cancer-associated fibroblasts (CAFs) are viewed as a promising therapeutic target, the design of rational therapy has been hampered by two key obstacles. First, attempts to ablate CAFs have resulted in significant toxicity because currently used biomarkers cannot effectively distinguish activated CAFs from non-cancer associated fibroblasts and mesenchymal progenitor cells. Second, it is unclear whether CAFs in different organs have different molecular and functional properties that necessitate organ-specific therapeutic designs. Our analyses uncovered COL11A1 as a highly specific biomarker of activated CAFs. Using COL11A1 as a 'seed', we identified co-expressed genes in 13 types of primary carcinoma in The Cancer Genome Atlas. We demonstrated that a molecular signature of activated CAFs is conserved in epithelial cancers regardless of organ site and transforming events within cancer cells, suggesting that targeting fibroblast activation should be effective in multiple cancers. We prioritized several potential pan-cancer therapeutic targets that are likely to have high specificity for activated CAFs and minimal toxicity in normal tissues., (Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
47. FOXC2 augments tumor propagation and metastasis in osteosarcoma.
- Author
-
Gozo MC, Jia D, Aspuria PJ, Cheon DJ, Miura N, Walts AE, Karlan BY, and Orsulic S
- Subjects
- Animals, Anoikis, Cell Adhesion, Cell Differentiation, Cell Line, Tumor, Cell Movement, Down-Regulation, Gene Expression Regulation, Neoplastic, Gene Silencing, Humans, Mice, Mice, Nude, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Signal Transduction, Bone Neoplasms pathology, Forkhead Transcription Factors metabolism, Lung Neoplasms secondary, Osteosarcoma pathology, Receptors, CXCR4 metabolism
- Abstract
Osteosarcoma is a highly malignant tumor that contains a small subpopulation of tumor-propagating cells (also known as tumor-initiating cells) characterized by drug resistance and high metastatic potential. The molecular mechanism by which tumor-propagating cells promote tumor growth is poorly understood. Here, we report that the transcription factor forkhead box C2 (FOXC2) is frequently expressed in human osteosarcomas and is important in maintaining osteosarcoma cells in a stem-like state. In osteosarcoma cell lines, we show that anoikis conditions stimulate FOXC2 expression. Downregulation of FOXC2 decreases anchorage-independent growth and invasion in vitro and lung metastasis in vivo, while overexpression of FOXC2 increases tumor propagation in vivo. In osteosarcoma cell lines, we demonstrate that high levels of FOXC2 are associated with and required for the expression of osteosarcoma tumor-propagating cell markers. In FOXC2 knockdown cell lines, we show that CXCR4, a downstream target of FOXC2, can restore osteosarcoma cell invasiveness and metastasis to the lung.
- Published
- 2016
- Full Text
- View/download PDF
48. LYMPHOCYTIC THYROIDITIS IS ASSOCIATED WITH INCREASED NUMBER OF BENIGN CERVICAL NODES AND FEWER CENTRAL NECK COMPARTMENT METASTATIC LYMPH NODES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
- Author
-
Donangelo I, Walts AE, Bresee C, and Braunstein GD
- Subjects
- Adult, Carcinoma complications, Cell Differentiation, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Neck, Neck Dissection, Retrospective Studies, Thyroid Neoplasms complications, Thyroidectomy, Thyroiditis, Autoimmune complications, Thyroiditis, Autoimmune pathology, Tumor Burden, Carcinoma epidemiology, Carcinoma pathology, Lymph Nodes pathology, Thyroid Neoplasms epidemiology, Thyroid Neoplasms pathology, Thyroiditis, Autoimmune epidemiology
- Abstract
Objective: Whether or not autoimmune thyroid disease influences the progression of differentiated thyroid cancer (DTC) remains controversial. Findings of previous studies are influenced by lead time bias and/or procedure bias selection. These biases can be reduced by studying a single-institution patient population that underwent a similar extent of surgical resection., Methods: From a cohort of 660 patients with DTC who underwent thyroidectomy, we retrospectively studied 357 patients who underwent total thyroidectomy and central compartment node dissection (CCND) for DTC between 2003 and 2013., Results: Forty-one percent (140/345) of study patients had lymphocytic thyroiditis (LT), and 30% (91/301) had serum positive for thyroglobulin antibody (TgAb). LT was reported in 78% of the TgAb-positive cases. Sixty percent (213/357) of cases had metastatic thyroid carcinoma in 1 or more neck lymph nodes (55% [198/357] central compartment, and 22% [77/356] lateral compartment). Patients with LT had fewer metastatic cervical lymph nodes than those with no LT (2.7 ± 4.7 vs 3.5 ± 4.8, respectively, P = .0285). Patients with positive TgAb and thyroiditis had a larger number of benign cervical lymph nodes removed than those with negative TgAb or no LT. No significant difference was observed in age, tumor size, multifocality, extrathyroidal extension, vascular invasion, or frequency of cervical lymph node metastasis between TgAb-negative and -positive cases or between cases with and without LT., Conclusion: Lymphocytic thyroiditis is associated with fewer central neck compartment metastatic lymph nodes and a larger number of excised reactive benign cervical lymph nodes. Whether this association indicates a protective role of thyroid autoimmunity in lymph node spreading remains unclear., Abbreviations: CCND = central compartment node dissection DTC = differentiated thyroid cancer HT = Hashimoto thyroiditis LT = lymphocytic thyroiditis TgAb = thyroglobulin antibody TPO = thyroid peroxidase.
- Published
- 2016
- Full Text
- View/download PDF
49. Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.
- Author
-
Huang F, Ma Z, Pollan S, Yuan X, Swartwood S, Gertych A, Rodriguez M, Mallick J, Bhele S, Guindi M, Dhall D, Walts AE, Bose S, de Peralta Venturina M, Marchevsky AM, Luthringer DJ, Feller SM, Berman B, Freeman MR, Alvord WG, Vande Woude G, Amin MB, and Knudsen BS
- Abstract
The limited clinical success of anti-HGF/MET drugs can be attributed to the lack of predictive biomarkers that adequately select patients for treatment. We demonstrate here that quantitative digital imaging of formalin fixed paraffin embedded tissues stained by immunohistochemistry can be used to measure signals from weakly staining antibodies and provides new opportunities to develop assays for detection of MET receptor activity. To establish a biomarker panel of MET activation, we employed seven antibodies measuring protein expression in the HGF/MET pathway in 20 cases and up to 80 cores from 18 human cancer types. The antibodies bind to epitopes in the extra (EC)- and intracellular (IC) domains of MET (MET4
EC , SP44_METIC , D1C2_METIC ), to MET-pY1234/pY1235, a marker of MET kinase activation, as well as to HGF, pSFK or pMAPK. Expression of HGF was determined in tumour cells (T_HGF) as well as in stroma surrounding cancer (St_HGF). Remarkably, MET4EC correlated more strongly with pMET ( r = 0.47) than SP44_METIC ( r = 0.21) or D1C2_METIC ( r = 0.08) across 18 cancer types. In addition, correlation coefficients of pMET and T_HGF ( r = 0.38) and pMET and pSFK ( r = 0.56) were high. Prediction models of MET activation reveal cancer-type specific differences in performance of MET4EC , SP44_METIC and anti-HGF antibodies. Thus, we conclude that assays to predict the response to HGF/MET inhibitors require a cancer-type specific antibody selection and should be developed in those cancer types in which they are employed clinically.- Published
- 2016
- Full Text
- View/download PDF
50. Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
- Author
-
Hiroshima K, Wu D, Hasegawa M, Koh E, Sekine Y, Ozaki D, Yusa T, Walts AE, Marchevsky AM, Nabeshima K, Tada Y, Shimada H, and Tagawa M
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Case-Control Studies, Cyclin-Dependent Kinase Inhibitor p16, Diagnosis, Differential, Epithelial Cells metabolism, Epithelial Cells pathology, Female, Humans, In Situ Hybridization, Fluorescence, Male, Mesothelioma metabolism, Middle Aged, Neoplasm Proteins genetics, Pleural Neoplasms metabolism, Biomarkers, Tumor metabolism, Mesothelioma pathology, Neoplasm Proteins metabolism, Pleural Neoplasms pathology
- Abstract
Background: Mesothelioma patients often present with serosal effusions, which are ideal for cytopathological diagnoses. However, the morphological overlap between malignant and benign mesothelial proliferation can make a conclusive cytological diagnosis of mesothelioma elusive because immunohistochemical staining does not discriminate definitively between the two in this setting. p16 is deleted in up to 80% of pleural mesotheliomas. The aim of this study was to establish the correlation between the p16 deletion status of the cell block with that of its corresponding tumor using fluorescence in situ hybridization (FISH) analysis for individual patient tumors., Methods: Twenty-two biopsies and 24 corresponding cell blocks, containing serosal effusions with atypical mesothelial cells from 22 patients with histologically confirmed pleural mesotheliomas, were analyzed with p16 FISH. Seventeen cell blocks consisting of serosal effusions with reactive mesothelial cells from nonmesothelioma cases were also analyzed. Combined immunofluorescence and FISH were also performed., Results: Seventeen of the 22 mesothelioma patients (77.3%) showed homozygous deletions of p16 in the tumor tissue and in the atypical mesothelial cells from the cell blocks. p16 FISH followed by immunofluorescence with EMA was helpful towards identifying the mesothelioma cells in the cell blocks., Conclusion: We confirmed that the p16 FISH results obtained from the cell blocks are as reliable as those from the tissue sections. Cell block analysis is recommended for patients with serosal effusions of unknown origins with the following methods: immunohistochemistry should be performed to validate the mesothelial origin, and p16 FISH should be performed to confirm malignancy. Diagn. Cytopathol. 2016;44:591-598. © 2016 Wiley Periodicals, Inc., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.